Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (21-30 of 418) with videos related to

Pageof 42
Sort By:
Biochemical Pharmacology|April 13, 2010
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinomaKeith T Flaherty, Igor Puzanov
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Gauging the Long-Term Benefits of Ipilimumab in MelanomaAntoni Ribas, Keith T Flaherty
Seminars in Cutaneous Medicine and Surgery|November 6, 2010
Targeted molecular therapy in melanomaIgor Puzanov, Keith T Flaherty
Cancer|July 15, 2010
BRAF, a target in melanoma: implications for solid tumor drug developmentKeith T Flaherty, Grant McArthur
The British Journal of Dermatology|June 26, 2025
The Rise of New Targets in MelanomaXue Bai, Keith T Flaherty
Nature Clinical Practice. Oncology|December 19, 2008
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?Keith T Flaherty, Weijing Sun
Current Opinion in Oncology|February 10, 2012
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insightsReinhard Dummer, Keith T Flaherty
Expert Reviews in Molecular Medicine|October 13, 2012
MEK and RAF inhibitors for BRAF-mutated cancersSarah Belden, Keith T Flaherty
Annals of Internal Medicine|August 4, 2018
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of AgeShiuh-Wen Luoh, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistanceAlexander Marzuka Alcalá, Keith T Flaherty
Pageof 42

Showing results (21-30 of 418) with videos related to

Sort By:
Pageof 42
Biochemical Pharmacology|April 13, 2010
Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinomaKeith T Flaherty, Igor Puzanov
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Gauging the Long-Term Benefits of Ipilimumab in MelanomaAntoni Ribas, Keith T Flaherty
Seminars in Cutaneous Medicine and Surgery|November 6, 2010
Targeted molecular therapy in melanomaIgor Puzanov, Keith T Flaherty
Cancer|July 15, 2010
BRAF, a target in melanoma: implications for solid tumor drug developmentKeith T Flaherty, Grant McArthur
The British Journal of Dermatology|June 26, 2025
The Rise of New Targets in MelanomaXue Bai, Keith T Flaherty
Nature Clinical Practice. Oncology|December 19, 2008
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?Keith T Flaherty, Weijing Sun
Current Opinion in Oncology|February 10, 2012
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insightsReinhard Dummer, Keith T Flaherty
Expert Reviews in Molecular Medicine|October 13, 2012
MEK and RAF inhibitors for BRAF-mutated cancersSarah Belden, Keith T Flaherty
Annals of Internal Medicine|August 4, 2018
When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of AgeShiuh-Wen Luoh, Keith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2012
BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistanceAlexander Marzuka Alcalá, Keith T Flaherty
Pageof 42